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An extremely rare lineage switch from T-cell lymphoblastic 
lymphoma into B-cell acute lymphoblastic leukemia at relapse
Niezwykle rzadki przypadek konwersji T-komórkowego ch oniaka limfoblastycznego w ostr  bia aczk  
limfoblastyczn  w nawrocie
Patrycja Rzepka1, Aleksandra Majewska1, Lech Sedlak1, Tomasz Oleksy1, Grzegorz Helbig2, 
S awomira Kyrcz-Krzemie 2
ABSTRACT
Lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is a neo-
plasm of precursor B or T-cells. These neoplastic cells may in  ltrate 
bone marrow and peripheral blood (acute lymphoblastic leukemia) or 
their presence is con  ned to nodal or extranodal sites with only minimal 
evidence of blood and bone marrow involvement (lymphoblastic lym-
phoma). Herein, we report a male patient with infrequent neurological 
manifestation of T-LBL who failed autologous hematopoietic stem cell 
transplantation (AHSCT). A lineage switch from T-cell lymphoblastic 
lymphoma into B-cell acute lymphoblastic leukemia was observed at 
relapse and this phenomenon has not been described so far. Our case 
demonstrates dif  culties which may occur in diagnosis and treatment 
of LBL/ALL. It should be underlined that neurological de  cits resulting 
from spinal cord compression may be the  rst symptom of lymphoma. 
A switch within the lymphoblastic line may occur but it is an extremely 
rare  nding. Its pathogenesis remains unclear, therefore further studies 
are highly required.
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Acute lymphoblastic leukemia/lymphoblastic lym-
phoma (ALL/LBL) is a neoplasm of lymphoblasts com-
mitted to the T-cell (T-ALL/T-LBL) or B-cell lineage 
(B-ALL/B-LBL). In LBL, lymphoblasts are found in 
nodal and extranodal sites whereas they involve bone 
marrow and blood in patients with ALL [1]. Rarely, 
the phenomenon called lineage switch may occur, in 
which the leukemic cell lineage at diagnosis converts 
to another lineage at relapse and most patients have 
the conversion from acute myeloid leukemia (AML) to 
ALL [2]. The long-term results after conventional che-
motherapy are unsatisfactory and therefore both au-
tologous (AHSCT) and allogeneic hematopoietic stem 
cell transplantations (alloHSCT) should be considered 
for high risk ALL/LBL [3]. Moreover, alloHSCT should 
be introduced in second and subsequent remission 
regardless of risk group [4, 5]. Herein, we report a 
35-year-old male who was initially diagnosed with 
T-LBL with atypical clinical presentation as a tumor 
mass in his cervical spine. He went into remission 
after chemotherapy and AHSCT. One year later he re-
lapsed as B-ALL and eventually underwent alloHSCT 
from his HLA-matched sibling. 
Case report
A 35-year-old male was admitted to our department 
on May 2009 with diagnosis of T-LBL. One year before 
a previously healthy male started to complain of acu-
te left shoulder pain, numbness of the lower limbs, 
progressive muscle weakness and dysuria. He was re-
ferred to the Neurological Department. On admission 
physical examination revealed incoordination and 
four limb weakness. No cranial nerve deficits were 
observed. He became paraplegic in next few days. Ma-
gnetic Resonance Imaging (MRI) of the central nervo-
us system (CNS) showed tumor mass which infiltrated 
the cervical spine. Due to progressive paraparesis, 
an emergency treatment consisting of corticosteroids 
(CS) was introduced despite the lack of histological 
examination. CS have been continued for three mon-
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plete hematological remission after first induction 
course. He had matched sibling donor and therefore 
he was proceeded to transplant procedure. Con-
ditioning consisted of cyclophosphamide and TBI 
(12Gy). Graft versus host disease (GVHD) prophylaxis 
included methotrexate and ciclosporin. The source of 
stem cells was granulocyte-colony stimulating factor 
(G-CSF)-mobilized peripheral blood. The patient was 
transplanted with 6.1×108/kg of mononuclear cells 
including 3.78×106 of CD34+ cells. Post-transplant 
period was complicated by skin changes consistent 
with graft versus host disease (GVHD) but promptly 
resolved after CS introduction. Currently, one year 
after transplant, patient remains in complete remis-
sion with no signs of GVHD. 
Discussion
T-lymphoblastic lymphoma frequently presents as a 
mediastinal mass, however it may involve any lymph 
node and extranodal site. CNS may be involved al-
though presentation at this site without nodal in-
volvement is rare [1]. It is estimated that less than 
10% of patients with T/B-ALL have CNS involvement 
at presentation [6,7]. It may have different clinical 
manifestations, e.g. headache, exophtalmus or uni-
lateral 7th nerve paresis (Bell’s palsy) [7]. However, 
spinal cord lesion as a first disease manifestation of 
LBL/ALL is rarely seen [8]. It was reported that spinal 
cord compression may mask the onset of B-cell diffu-
se large B-cell lymphoma, T-cell lymphoma and lym-
phoblastic lymphoma [9]. It should be mentioned that 
our patient developed neurological deficits without 
any other symptoms of lymphoma. Mediastinum and 
other nodal sites were free of disease. CS were given 
as a emergency treatment and this resulted in prompt 
resolution of neurological deficits. Lumbar puncture 
was not performed at that time and cerebrospinal flu-
id (CNS) was not evaluated towards the presence of 
lymphoblasts. The rapid introduction of CS did not 
allow to carry out proper diagnostic procedure. We 
may only suspect based on the further course of the 
disease that the presence of tumor mass in the ce-
rvical spine in our patient was consistent with the 
diagnosis of lymphoma, however tissue biopsy for hi-
stological study was not obtained. 
It is estimated that about 7% of acute leukemias 
may demonstrate the phenomenon of lineage switch. 
Most cases have shown the conversions from ALL to 
AML and they have been reported mostly in children 
[2,10]. There was only single published data on line-
age switch from AML to ALL [10, 11]. It was found that 
in most reported cases the time from diagnosis to 
conversion from AML to ALL was about 1 year and all 
these patients achieved remission after lineage switch 
[11]. In contrary conversions from ALL to AML were 
ths and this therapy resulted in complete resolution 
of neurological deficits. A repeated MRI of the CNS 
showed no abnormalities. CS have been slowly tape-
red. Five months later he noted nodular skin lesions 
in his back. Similar lesions have been also found in 
upper and lower limbs. On physical examination an 
increased left inguinal lymph node was detected. Po-
sitron emission tomography (PET) scan showed incre-
ased glucose uptake in the left groin and in the po-
sterior superior iliac crest. Histological examination 
of the excised lymph node was consistent with the 
diagnosis of T-LBL. Immunophenotyping of tumour 
cells was following: CD1a-, CD2-, cCD3+, CD4+, CD5-, 
CD7+, CD8-, CD10-/+, Tdt+, CD99+, CD34+, CD79a+, 
cyclinD1-, CD23-, CD20-, Ki67-100%. Biopsy of the 
skin lesion showed an infiltration consisting of lym-
phoblasts of T-cell origin. 
On admission to our Hematological Unit the 
patient was in good condition overall. Hemoglobin 
(Hgb) concentration and platelet count (PLT) were 
normal. White blood cell (WBC) count was 6.6×109/L 
with 73% of neutrophils, 20% of lymphocytes and 7% 
of monocytes. No blast cells were found in peripheral 
blood. Serum lactate dehydrogenase (LDH) activity, 
C-reactive protein (CRP) and B2-microglobulin (B2M) 
concentrations were within normal range. Bone mar-
row aspirate and trephine biopsy showed no abnor-
malities. Cytogenetic examination revealed diploid 
male karyotype and molecular studies were not 
performed.
CT scan of the thorax and abdomen revealed 
no lymphadenopathy. Cerebrospinal fluid was also 
normal. Patient received several cycles of intensive 
chemo therapy which consisted of CS, anthracycline, 
vinca alkaloid, cyclophosphamide, cytarabine and 
methotrexate with complete resolution of skin lesions 
and lymphadenopathy.
Due to aggressive nature of lymphoma he was 
offered AHSCT. As a conditioning patient received 
CAV regimen (cyclophosphamide, etoposide and 
cytarabine). He was transplanted with 6.63×108/kg 
of nucleated cells including 1.03×106 of CD34+ cells. 
Bone marrow regeneration was following: absolute 
neutrophil count (ANC) >0.5×109/L on day +17 and 
PLT count >50×109/L on day +20. Post-transplant 
period was free of severe complications. One year 
later patient was hospitalized in our Unit due to dura-
ble lumbosacral pain and night sweats. Blood tests 
were normal whereas marrow aspiration revealed 
95% of blast cells resembling lymphoblasts. Immu-
nophenotyping of blast cells was as follows: CD10+, 
CD19+, CD79a+, Tdt+, HLA-DR+. The diagnosis of 
B-ALL (common) was established. Cytogenetic study 
reveled diploid karyotype and molecular assays did 
not detect BCR-ABL and MLL-AF4 fusion proteins. 
Patient was started chemotherapy and achieved com-
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resistant to chemotherapy [10]. Herein, we present 
a patient who developed an extremely rare lineage 
switch from T-cell lymphoblastic lymphoma into B-cell 
lymphoblastic leukemia at relapse and this phenom-
enon hasn’t been described so far. It should be under-
lined that the diagnosis of T-LBL was confirmed by 
two independent and experienced pathologists based 
on lymph node and skin specimens. The pathogenesis 
of lineage switch remains unexplained, however some 
hypotheses were proposed. One of them assumes that 
the uncommitted progenitor cells originally have both 
myeloid and T- or B-lymphoid markers and later they 
maturate and differentiate toward the other lineage 
losing one lineage marker [12]. Another mechanism 
relates to prior chemotherapy which may eradicate 
the predominant leukemic clone and thereby causing 
the proliferation of subclones with different phenotype 
[11, 13]. In every case of lineage switch we should also 
consider the possibility of secondary neoplasia due to 
prior therapy. However in our patient there are some 
arguments against this theory. The interval between 
treatment and conversion was relatively short (1 year) 
and patient received agents which are not considered 
to be highly leukemogenic except cyclophosphamide 
at consolidation and conditioning. Moreover, we did 
not find any chromosomal abnormalities at relapse, 
particularly those involving chromosomes 5 and 7 
which preferentially occur at transformation [10]. 
In conclusion, our case demonstrates difficulties 
which may occur in diagnosis and treatment of LBL/
ALL. It should be underlined that neurological defi-
cits resulting from spinal cord compression may be 
the first symptom of lymphoma. A switch within the 
lymphoblastic line may occur but it is an extremely 
rare finding. Its pathogenesis remains unclear, there-
fore further studies are highly required. 
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